Syntax
Founded 2021 · 6 known investors
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.
Founders & leadership
Syntax was founded in 2021 by Ryan Clarke.
RC
Ryan ClarkeinFounder
Investors · 6
Funding
SEC filings, press & company announcements$28.8M disclosed across 2 rounds · 2026
Source: company announcements and press reports — follow each round's link for the claim.
Competitors · 5
by search overlapSenti Biosciences11 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Thumbnail for SyntheX10 shared keywordsSyntheX is a drug discovery company that engineers cells using its ToRFLEx platform to run target-centric, cell-based functional selection for challenging protein targets and novel mechanisms of action. It applies synthetic biology to identify drugs that modulate protein classes historically considered undruggable, such as those altering protein levels or interactions.
Abiologics9 shared keywordsAbiologics uses computational design tools to create protein-inspired molecules called Synteins, engineered to avoid the vulnerabilities of natural protein medicines while retaining biological function. The company develops these molecules as a new class of therapeutics with the aim of advancing candidates toward clinical development.
Synthesize9 shared keywordsSynthesize develops generative AI models that simulate human tissue responses to drugs and diseases for clinical trial design. The company helps biotech and pharmaceutical development teams de-risk trials, identify biomarkers, and extend early-phase data by generating synthetic patient cohorts.
Synlogic8 shared keywordsSynlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases. The company applies synthetic biology approaches to design programmable therapeutic candidates for patients.
Companies competing with Syntax for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Syntax do?
- Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation. The platform enables biopharma companies to speed up cell therapy development, reduce manufacturing costs, and expand their pipeline of potential treatments.
- Who founded Syntax?
- Syntax was founded by Ryan Clarke in 2021.
- Who are Syntax's investors?
- Syntax's investors include Astellas Venture Management LLC, DCVC (Data Collective), DCVC Bio, Draper Associates, Illumina Ventures, Portal Innovations.
- How much funding has Syntax raised?
- Syntax has disclosed $28.8M raised across 2 rounds.